CONCISE REPORTS

No primary association between LMP2 polymorphisms and extraspinal manifestations in spondyloarthropathies

Thomas Höhler, Thomas Schäper, Peter M Schneider, Frank Krummenauer, Christian Rittner, Karl-H Meyer zum Büschenfelde, Elisabeth Märker-Hermann

Abstract

Objective—To investigate the potential role of the HLA-linked LMP2 (low molecular weight protein) gene polymorphisms in conjunction with DR4 and DR7 on extraspinal disease manifestations in HLA-B27 positive patients with spondyloarthropathy.

Methods—172 patients with spondyloarthropathy, 46 healthy, HLA-B27 positive blood donors, and 99 unrelated controls were typed for HLA-class I and II antigens. LMP2 alleles were determined by polymerase chain reaction and subsequent restriction enzyme digestion.

Results—There were statistically nonsignificant increases of DR4 and DR7 in spondyloarthropathy subjects. However these differences did not relate to specific extraspinal manifestations. There were no significant differences in the LMP2 genotype distribution in the disease groups. All differences in LMP2 genotype frequencies disappeared when correcting for DR4, which was in linkage disequilibrium with the LMP2B allele.

Conclusions—There is no independent association between LMP2 genotypes and the occurrence of uveitis or peripheral arthritis in HLA-B27 positive subjects with spondyloarthropathy. DR4 and DR7 do not contribute to these disease manifestations.

(Ann Rheum Dis 1997;56:741–743)

The seronegative spondyloarthropathies encompass a variety of disorders, which include reactive arthritis, psoriatic arthritis, arthritis associated with inflammatory bowel disease, undifferentiated spondyloarthropathy, a subgroup of juvenile chronic arthritis, and ankylosing spondylitis as a prototype of this group of related disorders.1 These disorders are linked together by common clinical, laboratory, and genetic factors. The most prominent genetic factor is the association with HLA-B27, which is found in 95% of patients with ankylosing spondylitis and with lower prevalence in the other spondyloarthropathies.1

Linkage of HLA-B27 and ankylosing spondylitis has been comprehensively shown in a large family study, which suggested that the disease is inherited in an autosomal dominant pattern with a low penetrance of 20%.2 It is still unclear, however, whether other genes inside the MHC contribute to the disease risk or influence the risk for extraspinal disease manifestations as peripheral arthritis or uveitis.

Transcomplementation has been shown for HLA-B60, which increases the risk for ankylosing spondylitis more than threefold in B27 positive people.3 The contribution of HLA-DR genes to extraspinal disease manifestations is controversial. One group has reported an increase of DR7 in patients with peripheral arthritis5 and DR8 seems to predispose to uveitis in Japanese patients.7 A number of recent studies has focused on the association of MHC class II encoded TAP (transporter associated with antigen processing) and LMP (low molecular weight protein) genes, which participate in class I antigen processing.6–8

The LMP2 gene encodes a subunit of the proteasome, a cytoplasmic catalytic complex involved in the generation of antigenic peptides that are loaded on class I molecules within the endoplasmic reticulum.9

The LMP2 gene contains a coding polymorphism causing the exchange of arginine for histidine.9 Although nothing is known about the functional consequences of the LMP2 polymorphism, two recent studies reported an association of the LMP2 gene polymorphism with extraspinal disease in HLA-B27 positive subjects with ankylosing spondylitis.5,7 A third investigation could not confirm these findings.5 Unfortunately all three studies did not investigate the issue of linkage disequilibrium with class II antigens.

This study was done to test the hypothesis of an HLA-DR independent association between LMP2 genotypes and extraspinal manifestations in spondyloarthropathies. We did not find any such association. Deviations in LMP2 genotype frequencies could be explained by
Table 1: LMP2 genotype distribution in the investigated groups. LMP2BB genotypes were compared against LMP2AB and AA genotypes. The significant differences in genotype distribution were between DR4 positive patients with spondyloarthropathy (SpA) compared with DR4 negative patients with SpA (*) and between DR4 positive patients with SpA compared with DR4 negative, B27 controls (†) (p < 0.03)

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Number</th>
<th>%</th>
<th>Number</th>
<th>%</th>
<th>Number</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (n=99)</td>
<td>5</td>
<td>52.6</td>
<td>4</td>
<td>44.4</td>
<td>1</td>
<td>10.2</td>
</tr>
<tr>
<td>B27 positive controls (n=46)</td>
<td>3</td>
<td>6.5</td>
<td>21</td>
<td>45.7</td>
<td>22</td>
<td>47.8</td>
</tr>
<tr>
<td>B27 positive controls, DR4 negative (n=38)</td>
<td>3</td>
<td>7.9</td>
<td>18</td>
<td>47.4</td>
<td>17†</td>
<td>44.8†</td>
</tr>
<tr>
<td>SpA (n=172)</td>
<td>12</td>
<td>7.0</td>
<td>64</td>
<td>37.2</td>
<td>92</td>
<td>55.8</td>
</tr>
<tr>
<td>Ankylosing spondylitis (n=114)</td>
<td>9</td>
<td>6.4</td>
<td>52</td>
<td>37.9</td>
<td>80</td>
<td>56.7</td>
</tr>
<tr>
<td>SpA, without peripheral arthritis and uveitis (n=79)</td>
<td>6</td>
<td>7.6</td>
<td>32</td>
<td>40.5</td>
<td>41</td>
<td>51.9</td>
</tr>
<tr>
<td>SpA, DR4 negative (n=119)</td>
<td>10</td>
<td>8.4</td>
<td>49</td>
<td>41.2</td>
<td>60*†</td>
<td>50.4*†</td>
</tr>
<tr>
<td>SpA, DR4 positive (n=53)</td>
<td>2</td>
<td>3.8</td>
<td>15</td>
<td>28.3</td>
<td>36‡</td>
<td>67.9‡</td>
</tr>
<tr>
<td>SpA and peripheral arthritis (n=72)</td>
<td>5</td>
<td>6.9</td>
<td>27</td>
<td>37.5</td>
<td>40</td>
<td>55.6</td>
</tr>
<tr>
<td>SpA and peripheral arthritis, DR4 negative (n=52)</td>
<td>5</td>
<td>9.6</td>
<td>21</td>
<td>40.4</td>
<td>26</td>
<td>50.0</td>
</tr>
<tr>
<td>SpA and uveitis (n=46)</td>
<td>2</td>
<td>4.4</td>
<td>16</td>
<td>34.8</td>
<td>28</td>
<td>60.9</td>
</tr>
<tr>
<td>SpA and uveitis, DR4 negative (n=30)</td>
<td>2</td>
<td>6.7</td>
<td>13</td>
<td>43.3</td>
<td>15</td>
<td>50.0</td>
</tr>
<tr>
<td>SpA, peripheral arthritis and uveitis (n=25)</td>
<td>1</td>
<td>4.0</td>
<td>11</td>
<td>44.0</td>
<td>13</td>
<td>52.0</td>
</tr>
<tr>
<td>SpA, peripheral arthritis and uveitis, DR4 negative (n=16)</td>
<td>1</td>
<td>6.3</td>
<td>9</td>
<td>56.3</td>
<td>6</td>
<td>37.5</td>
</tr>
</tbody>
</table>

* p = 0.04; odds ratio 2.08; 99% confidence intervals (0.8, 8.15); † p = 0.03; odds ratio 2.62; 99% confidence intervals (0.78, 8.79); ‡ p = 27%.

**LMP2 GENE POLYMORPHISM**

PCR primers and conditions were as described previously.1 After PCR amplification samples were digested with HhaI (New England Biolabs) and alleles were assigned after electrophoresis on a 2.5 % agarose gel.

**STATISTICAL ANALYSIS**

An extensive explorative statistical analysis was performed to detect possible differences in the proportion of LMP2BB versus LMP2AA/AB among several subgroups. Statistical analysis was done using the two sided exact Fisher test. Odds ratio and its 99% two sided confidence intervals are presented. The confidence levels were raised from the usual 95% to 99% because no adjustment for multiple comparisons was performed. The posteriori power π was calculated using the Casagrande/Pike/Smith approximation.11

**Results**

**DR ANTIGENS**

For DR4 there was an increase of borderline significance in the spondyloarthropathy group compared with HLA-B27 controls (32% v 17.4%; p<0.07). DR4 frequencies were similar in all investigated spondyloarthropathy subgroups (30.6% in patients with peripheral arthritis and 34.8% in patients with uveitis). There was a non-significant increase for DR7 in the spondyloarthropathy group compared with B27 controls. A similar difference was observed when comparing DR7 frequencies in spondyloarthropathy patients with and without peripheral arthritis (15% v 25%, respectively; p<0.1).

**LMP2 POLYMORPHISMS**

Table 1 shows the data on LMP2 genotype frequencies in the different groups. We found no significant differences in the genotype distribution between healthy B27 controls and the entire spondyloarthropathy group. However, the LMP2BB genotype was enriched in DR4 positive patients with spondyloarthropathy (67.9%) compared with B27 positive, DR4 negative controls (44.4%; p<0.03; odds ratio
2.6) and with DR4 negative patients with spondyloarthritis (50.4%; p<0.04; odds ratio 0.48) suggesting linkage disequilibrium of this allele to LMP2B. The non-significant enrichment of the BB genotype in patients with uveitis (60.9% vs 47.8% in B27 positive controls) was almost equalised when DR4 positive subjects were removed from both groups (50.0% vs 44.4% in B27 positive, DR4 negative controls). To exclude the introduction of a bias by choosing a heterogenous patient group encompassing a variety of disorders we analysed the ankylosing spondylitis patients separately. The LMP2BB genotype frequency in these patients matched almost exactly that in the entire spondyloarthropathy group (56.7% in ankylosing spondylitis vs 55.8% in the spondyloarthropathy group). Neither subjects with peripheral joint involvement nor those with uveitis and peripheral arthritis showed any significant deviation in the LMP2 genotype distribution. LMP2A homozygotes were observed in all groups.

Discussion

Our study shows that there is no independent association between the occurrence of uveitis and peripheral arthritis and the presence of the LMP2 BB genotype in HLA-B27 positive patients with seronegative spondyloarthritis. Observed differences in LMP2BB genotypes are easily explained by the differences of DR4 frequencies in the investigated subgroups. After correction for DR4, the frequency of LMP2B homozygotes was similar in all spondyloarthropathy subgroups (51.9% in subjects with spondyloarthritis without peripheral arthritis and uveitis; 50% in subjects with spondyloarthritis and peripheral arthritis; 50% in subjects with spondyloarthropathy and uveitis).

This work contains essential parts of the doctoral thesis of Thomas Schäper. We thank Dr Peter Hasenclever, Karl-Aschoff-Klinik Bad Kreuznach, for the excellent cooperation and the inclusion of numerous patients into our study.